Who is sponsoring NCT04731285?

NCT04731285 is sponsored by Beijing Anzhen Hospital.

What drugs are being tested in NCT04731285?

Interventions in NCT04731285: Pressure wire fractional flow reserve, CFD-based RuiXin-FFR.

What condition does NCT04731285 study?

NCT04731285 studies Coronary Artery Disease, Myocardial Ischemia, Myocardial Fractional Flow Reserve.

Is NCT04731285 still recruiting?

NCT04731285 is currently completed. Last updated 5 September 2021.

Last reviewed 2021-09-05 · How we verify

NCT04731285

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Accuracy of CFD-based RuiXin-FFR by Comparing With Pressure-wire-based FFR

Completed Last updated 5 September 2021

What this trial tests

trial testing Pressure wire fractional flow reserve in Coronary Artery Disease in 316 participants. Completed in 31 August 2020.

Timeline

13 March 2019

Primary endpoint
14 May 2020

31 August 2020

Quick facts

Lead sponsor	Beijing Anzhen Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	316
Start date	13 March 2019
Primary completion	14 May 2020
Estimated completion	31 August 2020
Sites	1 location across China

Drugs / interventions tested

Pressure wire fractional flow reserve
CFD-based RuiXin-FFR

Conditions studied

Coronary Artery Disease — all drugs for Coronary Artery Disease →
Myocardial Ischemia — all drugs for Myocardial Ischemia →
Myocardial Fractional Flow Reserve — all drugs for Myocardial Fractional Flow Reserve →

Sponsor

Beijing Anzhen Hospital

Who can join

18 and older, any sex, with Coronary Artery Disease or Myocardial Ischemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Coronary Artery Disease (CAD) is the top killer nowadays. Pressure-wire-based Fractional Flow Reserve (FFR) is the gold standard for measuring ischemia in coronary arteries. CFD-based RuiXin-FFR, which is noninvasive, is developed recently. But its accuracy is not verified. This is a multi-center and prospective study to evaluate the sensitivity, specificity, and accuracy of CFD-based RuiXin-FFR compared with wire-based FFR.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Diagnostic accuracy of CT-FFR with a new coarse-to-fine subpixel algorithm in detecting lesion-specific ischemia: a prospective multicenter study.
Zeng Y, Wang X, Tang Z, Li T, et al · · 2024 · cited 8× · PMID 37453536 · DOI 10.1016/j.rec.2023.05.008

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting

Other Beijing Anzhen Hospital trials

Trials by the same sponsor.

NCT07521488 — LLM-Based Intelligent Health Management Assistant in Life-Cycle Health Management of Cardiac Surgery Patients · NA · not yet recruiting
NCT07470814 — Multidisciplinary Collaborative Care System for Acute Myocardial Infarction Complicated With Cardiogenic Shock · not yet recruiting
NCT07444372 — Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation · NA · not yet recruiting
NCT07256197 — PCSK9 Inhibitors in the Treatment of Calcific Aortic Stenosis · Phase 3 · not yet recruiting
NCT07485101 — Glycemic Targets During CPB in Elderly Diabetes · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04731285 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Anzhen Hospital
Last refreshed: 5 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04731285.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing